1. 52-week trial tested low-dose methotrexate for knee OA.
2. No significant difference in pain reduction vs. placebo.
3. 215 participants, mean age 60.4, 89% women.
4. Elevated liver enzymes noted in methotrexate group.
5. High dropout rate with only 175 completing trial.
6. No serious adverse events related to treatment.
7. Subgroup analysis showed insufficient sample size for definite conclusions.

Source: JAMA Internal Medicine